LLLT vs. IPL for Meibomian Gland Dysfunction: What We Know

Low-level light therapy (LLLT) may relieve meibomian gland dysfunction symptoms at least as well as intense pulsed light (IPL), but the best direct comparison lasted only two weeks and enrolled 40 patients. That makes the result interesting, not practice-settling.

Meibomian gland dysfunction, or MGD, blocks the eyelid glands that release the oily outer layer of the tear film. When that lipid layer fails, tears evaporate faster and eyes can burn, sting, feel gritty, or blur. Warm compresses and lubricating drops can help, but they often leave the underlying gland obstruction and lid-margin inflammation largely intact.

IPL has the deeper clinical track record. LLLT has a plausible but less tested alternative mechanism, and a small randomized trial gave it an early edge on symptoms. The question is not whether light can make dry eyes feel better for some people. It can. The unresolved question is which device helps which patient, for how long, and whether combining them adds anything beyond IPL alone.

The only direct LLLT-versus-IPL trial

In a prospective randomized comparative study, Giannaccare et al. assigned 40 patients with MGD to LLLT or IPL, 20 per group. Two weeks after treatment, the LLLT group had a larger reduction in Standard Patient Evaluation of Eye Dryness (SPEED) symptom scores: minus 9.9 ± 3.2 points, versus minus 6.75 ± 4.5 points with IPL. The between-group difference was 3.15 points and was statistically significant (P=0.014).

LLLT also increased tear meniscus height by 0.06 ± 0.10 mm, while IPL changed it by minus 0.01 ± 0.014 mm; the between-group difference was 0.07 mm (P=0.040). Tear meniscus height estimates the volume of tears sitting at the lower lid margin. Both groups improved significantly from baseline on SPEED (P<0.001).

Those results do not show that LLLT repaired meibomian glands more effectively. Noninvasive tear breakup time, redness score, meiboscore, and measured meibomian gland loss did not change significantly in either group. The trial found a short-term symptom advantage and a difference in an examiner-measured tear-volume marker, not a demonstrated structural advantage.

LLLT has one promising head-to-head result. It does not yet have a confirmed long-term advantage over IPL.

The study's design explains the caution. It was a pilot-sized trial, follow-up ended two weeks after treatment, and neither patients nor treating clinicians were masked to the assigned therapy. That matters especially for SPEED, a patient-reported symptom questionnaire. Expectations can influence symptom reporting when everyone knows which treatment was delivered. The apparent LLLT advantage could be real, partly shaped by unblinding, or both.

The two devices also came from the same manufacturer. The report does not resolve whether device settings or treatment protocols were equally optimized for both arms. That does not establish bias; it leaves a reasonable source of uncertainty.

IPL has the broader evidence base

IPL delivers polychromatic light, roughly 515 to 1200 nm. Its proposed effects include heating thickened meibum and treating lid-margin telangiectasia through selective light absorption. Those mechanisms fit established photothermal principles, but clinical benefit—not a neat mechanism diagram—is the reason to consider treatment.

A larger prospective randomized study by Ren et al. enrolled 130 patients, or 260 eyes, and compared three monthly sessions of IPL plus meibomian gland expression with near-infrared light (NIL) plus gland expression. Both treatments improved dry-eye symptoms and gland function. IPL significantly improved dryness score, total symptom score, gland expressibility, and secretion quality after treatment.

In the subgroup with severe meibomian gland dropout, IPL outperformed NIL at two months for blurred vision, photophobia, burning, increased secretions, and total symptom score (all P<0.05). NIL also produced significant symptom improvement in patients with mild-to-moderate gland dropout.

This does not contradict the LLLT study as cleanly as it first appears to. NIL at 800 to 1100 nm is not the same intervention as dual-band LLLT at 465 and 625 nm. Ren et al. also gave both groups meibomian gland expression, a treatment that can improve obstructed glands on its own. The trial therefore tests two light-plus-expression strategies, not the isolated effect of either light modality.

Still, the study supplies a useful clinical boundary: in patients with severe gland dropout, IPL performed better than the near-infrared comparator used in that trial. Reviews of the field, including a 2024 clinical review and a 2024 ophthalmology review, place IPL at the center of current in-office light treatment for appropriately selected MGD patients.

Why combination treatment remains an unanswered question

Many clinics pair IPL with LLLT, usually blue 465-nm and red 625-nm light. The rationale differs from IPL's photothermal approach: blue light is intended to act on bacterial porphyrins, while red light is proposed to influence cellular energy signaling and inflammation. The clinical studies do not yet prove those proposed pathways in human meibomian gland tissue.

A 2022 systematic review of six IPL-plus-LLLT studies found improvements in Ocular Surface Disease Index scores, MGD measures, meiboscore, tear-film stability, and lipid-layer thickness. Tear meniscus height and Schirmer testing did not change. Findings for tear osmolarity and corneal fluorescein staining conflicted across studies.

The central limitation is simpler than the marketing brochure: none of the included studies used an IPL-alone control group. A combined protocol may outperform IPL, equal IPL, or merely package IPL with another treatment that feels technologically persuasive. Marques et al. explicitly identified the missing IPL-alone comparison.

Prospective observational work, including Marta et al., supports improvement after combined treatment, but before-and-after improvement cannot establish that LLLT supplied the added benefit. MGD symptoms also fluctuate, and treatment visits often include lid care or other changes.

Demodex and ocular graft-versus-host disease: useful extensions, limited proof

Light treatment is reaching more complicated eye-surface problems. A 2025 retrospective, single-center study by Farrant et al. reported improvement after IPL plus blue and red LLLT in people with Demodex-associated blepharitis and concurrent MGD. The cohort lacked a control group and used variable treatment frequencies, so it cannot show that the light protocol caused the improvement or beat standard Demodex management.

In chronic ocular graft-versus-host disease, Song et al. retrospectively evaluated IPL plus gland expression in 18 patients, one eye each. At four weeks after the final session, OSDI, SPEED, meibum expressibility, and meibum quality improved significantly; at 12 weeks, OSDI, SPEED, and expressibility remained significantly improved. No IPL-related adverse events were reported. This is encouraging feasibility data in a difficult population, not a controlled demonstration of efficacy.

Who should consider what?

For a patient with confirmed MGD who is eligible for IPL, the evidence currently favors IPL as the better-supported in-office light option, particularly when gland dropout is severe. Its use should follow an ophthalmic evaluation, because dry-eye symptoms can come from several overlapping problems, including aqueous tear deficiency, allergy, corneal disease, and eyelid inflammation.

IPL is contraindicated in Fitzpatrick skin types V and VI because melanin absorption can raise the risk of pigment changes, including hypopigmentation. The available evidence does not document the same skin-type restriction for LLLT. That makes LLLT worth discussing when IPL is unsuitable, but it does not convert one short, unblinded pilot into proof of equivalent long-term effectiveness.

There are no comparative cost or access data in these studies, so claims that one option is cheaper or more practical need local pricing rather than scientific guesswork. The study that would change the conversation would randomize at least 100 patients per arm across multiple centers, mask outcome assessment where possible, follow patients for a year, and compare IPL alone, LLLT alone, and the combination without routine gland expression muddying the comparison. Until then, IPL has the stronger foundation; LLLT has a legitimate lead worth testing again.